TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03901365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuroscience pain education
Description: In Neuroscience pain education (NPE) sessions, patients were informed about the pain experience and the neurophysiological process about pain. NPE was performed by the method proposed by Louw et al (12). NPE was administered 4 sessions per week for four weeks. Trainings were conducted in the form of face-to-face interview and 45-50 minutes of one-to-one sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional patient education
Description: In traditional patient education (TPE) sessions were aimed to explain to patients a proposed treatment or efficacy of a certain manual therapy technique or approach, have focused heavily on biomechanical and anatomical models. These models would imply that injury, disease, and muscle guarding may lead to altered movement patterns, asymmetrical loading, and resultant pain and dysfunction. TPE was administered 4 sessions per week for four weeks. Trainings were conducted in the form of face-to-face interview and 45-50 minutes of one-to-one sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Manual therapy (MT) was individualized according to each patient's response to treatment. In this method, the physiotherapist identifies and performs techniques suitable for the patient's symptoms. If the selected techniques do not have a direct positive effect on the patient's symptoms, they are replaced with other techniques.MT were performed in a total of 8 sessions, held twice a week for 4 weeks. Treatment sessions lasted an average of 40-45 minute.The entire treatment program was carried out by the same physiotherapist who is trained and experienced in this area.
Study: NCT03617510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felbinac Trometamol Injection
Description: Felbinac Trometamol Injection will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the drug was given 7 times,3 times/day,once every 8 hours. It means the drug was given 3 times on D3 and D4,once on D5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Normal saline will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the Placebo was given 7 times,3 times/day,once every 8 hours.It means the Placebo was given 3 times on D3 and D4,once on D5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Normal saline will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the Placebo was given 7 times,3 times/day,once every 8 hours.It means the Placebo was given 3 times on D3 and D4,once on D5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Normal saline will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the Placebo was given 7 times,3 times/day,once every 8 hours.It means the Placebo was given 3 times on D3 and D4,once on D5.
Study: NCT03901365

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Manual therapy (MT) was individualized according to each patient's response to treatment. In this method, the physiotherapist identifies and performs techniques suitable for the patient's symptoms. If the selected techniques do not have a direct positive effect on the patient's symptoms, they are replaced with other techniques.MT were performed in a total of 8 sessions, held twice a week for 4 weeks. Treatment sessions lasted an average of 40-45 minute.The entire treatment program was carried out by the same physiotherapist who is trained and experienced in this area.
Study: NCT01613586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT03788356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing
Description: Diaphragmatic breathing exercise
Study: NCT04037982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic pancreaticoduodenectomy
Description: During laparoscopic surgery, the surgeon makes several smaller incisions in your abdomen and inserts special instruments, including a camera that transmits video to a monitor in the operating room. The surgeon watches the monitor to guide the surgical tools in performing the Whipple procedure. Laparoscopic surgery is a type of minimally invasive surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open pancreaticoduodenectomy
Description: During an open procedure, your surgeon makes an incision in your abdomen in order to access your pancreas. This is the most common approach and the most studied.
Study: NCT02102269

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: actimove sling
Study: NCT03617510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Normal saline will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the Placebo was given 7 times,3 times/day,once every 8 hours.It means the Placebo was given 3 times on D3 and D4,once on D5.
Study: NCT03064230

Intervention type: OTHER
Intervention: QoL questionnaire SF-12 and and a screening questionnaire
Description: patient were asked to fill questionnaires

Intervention type: OTHER
Intervention: QoL questionnaire SF-12 and and a screening questionnaire
Description: patient were asked to fill questionnaires
Study: NCT01649804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg intravenously every 4 weeks for 104 weeks
Study: NCT00901407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamotrigine
Description: lamotrigine augmentation 25 to 100 mg tablets, 25 to 200 mg bid,10 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo: 1-2 tablets bid; 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine
Description: open label paroxetine 10 to 50 mg, at bedtime for 18 weeks (8 weeks prior to randomization and 10 weeks after)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paroxetine
Description: open label paroxetine 10 to 50 mg, at bedtime for 18 weeks (8 weeks prior to randomization and 10 weeks after)
Study: NCT02488850

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SABR
Study: NCT03873610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress and Symptom Management Program 1
Description: The Stress and Symptom Management Program 1 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress and Symptom Management Program 2
Description: The Stress and Symptom Management Program 2 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.
Study: NCT00924079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine
Description: oral dosage form, 66 mg, single dose
Study: NCT05038046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) daycare model
Description: Traditional Chinese Medical (TCM) daycare model provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage for meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total).
Study: NCT00751218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desloratadine
Description: desloratadine, 5mg oral tablets, once daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, once daily for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetirizine
Description: cetirizine, 10 mg capsules once daily for 28 days
Study: NCT00778804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telemedicine
Description: Weekly transmission of health status (weight, activity, BP etc.) via the Internet with feeedback and reinforcement
Study: NCT04017208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2713
Description: Administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered intravenously
Study: NCT04347538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Nasal Irrigation
Description: Saline nasal irrigation BID

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline with Baby Shampoo Nasal Irrigation
Description: Saline with 1/2 teaspoon Baby Shampoo Nasal Irrigation.
Study: NCT01318642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine on days 1, 8, and 15, followed by placebo on days 1 and 15 of every 28 day cycle.
Study: NCT04336969

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 4T Education and Care
Description: CGM data will be used to create customized weekly feedback to the participant/family by secure MyChart message.
Study: NCT01969578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide + triptorelin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin + Doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin + Paclitaxel
Study: NCT03551119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: See previous description

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced usual care
Description: See previous description
Study: NCT01318642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine on days 1, 8, and 15, followed by placebo on days 1 and 15 of every 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: Gemcitabine on days 1, 8, and 15, followed by AMG 479 20 mg/kg on days 1 and 15 of every 28 day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Gemcitabine on Days 1, 8, and 15 followed by Placebo 20 mg/kg on days 1 and 15 of every 28 day cycle
Study: NCT03408262

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-EnvCN54
Description: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-EnvCN54
Description: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-EnvCN54
Description: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-EnvCN54
Description: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-EnvCN54
Description: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-EnvCN54
Description: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-CN54
Description: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
Study: NCT03749473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice + Immediate
Description: Participants in the choice + immediate goal arm will choose a step goal and must attempt to achieve this new step goal immediately at the start of the study.
Study: NCT03408262

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-CN54
Description: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-CN54
Description: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-CN54
Description: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CN54gp140/MPLA
Description: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CN54gp140/MPLA
Description: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CN54gp140/MPLA
Description: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant
Study: NCT01710150

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: CTI ablation alone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTI ablation and Pulmonary vein isolation (PVI)
Study: NCT02990858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140 SC injections
Study: NCT03408262

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CN54gp140/MPLA
Description: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CN54gp140/MPLA
Description: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CN54gp140/MPLA
Description: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CN54gp140/MPLA
Description: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CN54gp140/MPLA
Description: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant
Study: NCT00609648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Assisted Relaxation Learning
Description: A self-paced computer program for reducing dental injection fear.
Study: NCT03749473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice + Gradual
Description: Participants in the choice + gradual goal arm will choose a step goal and will gradually work towards the chosen step goal over the first 8-weeks of the study.
Study: NCT00609648

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pamphlet
Description: A pamphlet reassuring patients about dental injections.
Study: NCT01353638

Intervention type: DRUG
Group type: OTHER
Intervention: Dipeptiven (Alanyl-glutamine-dipeptide)
Description: Two arms (A and B) and two treatment periods (1 and 2) are scheduled for this study. Each arm includes 14 patients. Schedule arm A: Treatment period 1 with one single peritoneal dialysis exchange (standard PD solution) with Alanyl-Glutamine-Dipeptide as add-on. 17,4 ml Dipeptiven (=3,48g N(2)-L Alanyl-L-Glutamin) will be dissolved at a final concentration of 0,174 %(= 8 mmol/l) in 2 liters of Dianeal®PD4 (at PH:5,5; Glucose-Concentration 3,86 %). After a wash out period (28 days + max 7 days), arm A undergoes treatment period 2, that is one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide. Schedule Arm B: Treatment period 1 with one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide followed by wash-out. Treatment period 2 for arm B includes one single peritoneal dialysis exchange with standard PD solution with Alanyl-Glutamine-Dipeptide as add-on. Dosages remain exactly the same.

Intervention type: DRUG
Group type: OTHER
Intervention: Dipeptiven (Alanyl-glutamine-dipeptide)
Description: Two arms (A and B) and two treatment periods (1 and 2) are scheduled for this study. Each arm includes 14 patients. Schedule arm A: Treatment period 1 with one single peritoneal dialysis exchange (standard PD solution) with Alanyl-Glutamine-Dipeptide as add-on. 17,4 ml Dipeptiven (=3,48g N(2)-L Alanyl-L-Glutamin) will be dissolved at a final concentration of 0,174 %(= 8 mmol/l) in 2 liters of Dianeal®PD4 (at PH:5,5; Glucose-Concentration 3,86 %). After a wash out period (28 days + max 7 days), arm A undergoes treatment period 2, that is one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide. Schedule Arm B: Treatment period 1 with one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide followed by wash-out. Treatment period 2 for arm B includes one single peritoneal dialysis exchange with standard PD solution with Alanyl-Glutamine-Dipeptide as add-on. Dosages remain exactly the same.
Study: NCT02959151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T cell
Description: CAR-T cells are generated by T cells from the patients or a suitable donor transfected by CAR-lentivirus vectors. There are three options for CAR-targets: GPC3 for hepatocellular carcinoma;mesothelin for pancreatic cancer metastatic; CEA for colorectal cancer metastatic.
Study: NCT03749473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned + Immediate
Description: Participants in the assigned + immediate goal arm will be assigned a step goal and must attempt to achieve this new step goal immediately at the start of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned + Gradual
Description: Participants in the assigned + gradual goal arm will be assigned a step goal and will gradually work towards the chosen step goal over the first 8-weeks of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily performance feedback
Description: Participants will receive daily performance feedback on their daily step count.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily performance feedback
Description: Participants will receive daily performance feedback on their daily step count.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily performance feedback
Description: Participants will receive daily performance feedback on their daily step count.
Study: NCT01484106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid Resuscitation
Description: In the Treatment group, this information will be used in a specific 4-hour treatment algorithm to guide fluid administration that is summarized in Figure 1. The information provided by the NICOM in response to the fluid bolus will be used to assess whether the subject is fluid responsive (FR).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study: NCT04735354

Intervention type: DRUG
Intervention: sacubitril/valsartan
Description: There was no treatment allocation. Patients administered sacubitril/valsartan by prescription that started before inclusion of the patient into the study were enrolled.
Study: NCT03749473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily performance feedback
Description: Participants will receive daily performance feedback on their daily step count.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily performance feedback
Description: Participants will receive daily performance feedback on their daily step count.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification
Description: All participants in the intervention arms will be entered into a gamification platform that has points and levels designed to incorporate insights from behavioral economics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification
Description: All participants in the intervention arms will be entered into a gamification platform that has points and levels designed to incorporate insights from behavioral economics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification
Description: All participants in the intervention arms will be entered into a gamification platform that has points and levels designed to incorporate insights from behavioral economics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification
Description: All participants in the intervention arms will be entered into a gamification platform that has points and levels designed to incorporate insights from behavioral economics.
Study: NCT00562471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adhibit Adhesion Prevention Gel
Description: A resorbable hydrogel, which adheres to itself and the tissues it contacts, is approved for use in sealing vascular reconstructions. The hydrogel is formed when two synthetic derivatized polyethylene glycol (PEG) polymers are mixed together and applied to tissue. Using a gas-assisted delivery device, the hydrogel is sprayed over all myomectomy suture lines and all surgically treated areas during the myomectomy surgery. The hydrogel is totally resorbed within 30 days post-application.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Comparator
Description: standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with Ringers Lactate solution following surgery and 300 to 500mL of solultion left in the pelvic cavity immediately prior to wound closure
Study: NCT06448078

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External chest wall fixator
Description: External chest wall fixator is applied in the form of external bonding to the rib fracture area
Study: NCT03605212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat
Description: Intervention is orally administered to patients in this arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Intervention is orally administered to patients in this arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Intervention is orally administered to patients in this arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Intervention is orally administered to patients in this arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Intervention is orally administered to patients in this arm.
Study: NCT02083081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community level intervention
Description: Community intervention plus individual counseling